TRIPTODUR KIT Drug Patent Profile
✉ Email this page to a colleague
When do Triptodur Kit patents expire, and what generic alternatives are available?
Triptodur Kit is a drug marketed by Azurity and is included in one NDA. There is one patent protecting this drug.
This drug has forty-six patent family members in thirty-one countries.
The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.
DrugPatentWatch® Generic Entry Outlook for Triptodur Kit
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 29, 2024. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TRIPTODUR KIT
| International Patents: | 46 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | TRIPTODUR KIT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TRIPTODUR KIT
Generic Entry Date for TRIPTODUR KIT*:
Constraining patent/regulatory exclusivity:
TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY NDA:
Dosage:
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for TRIPTODUR KIT
US Patents and Regulatory Information for TRIPTODUR KIT
TRIPTODUR KIT is protected by one US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRIPTODUR KIT is ⤷ Try a Trial.
This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TRIPTODUR KIT
Slow release pharmaceutical composition made of microgranules
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting TRIPTODUR KIT
TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | TRIPTODUR KIT | triptorelin pamoate | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 208956-001 | Jun 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Azurity | TRIPTODUR KIT | triptorelin pamoate | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 208956-001 | Jun 29, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRIPTODUR KIT
See the table below for patents covering TRIPTODUR KIT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Montenegro | 00959 | FARMACEUTSKA KOMPOZICIJA SA SPORIM OSLOBAĐANJEM KOJA JE FORMIRANA OD MIKROČESTICA (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES) | ⤷ Try a Trial |
| Malaysia | 150450 | SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES | ⤷ Try a Trial |
| Serbia | 55591 | FARMACEUTSKA KOMPOZICIJA SA SPORIM OSLOBAĐANJEM PRIPREMLJENA OD MIKROČESTICA (SLOW RELEASE PHARMACEUTICAL COMPOSITION MADE OF MICROPARTICLES) | ⤷ Try a Trial |
| Spain | 2694401 | ⤷ Try a Trial | |
| South Korea | 101631475 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
